152 results about "Hypromellose" patented technology

The invention relates to a composite hydroxypropyl methylcellulose skeleton sustained-release material and a preparation method thereof, and belongs to the technical field of drug sustained release. The sustained-release material is prepared from 70 to 90 parts of hydroxypropyl methylcellulose (HPMC), 10 to 20 parts of sodium alginate, 8 to 15 parts of chitosan, 0.1 to 0.2 part of Omega-3 fatty acid, 0.05 to 0.06 part of vitamin D, 2.5 to 5 parts of soluble calcium salt-zinc salt composite cross-linking agent, 0.5 to 1.5 parts of hydrolyzable cross-linking agent, 3 to 10 parts of enzyme sensitive auxiliary material, 1 to 5 parts of pore-foaming agent and 2 to 8 parts of hydrophobic blocking agent. The preparation method comprises the steps of raw material pretreatment and dry mixing, active component dispersion liquid preparation, wet granulation and primary cross-linking, secondary cross-linking and drying, vacuum drying and size stabilization, curing and packaging and the like. The sustained-release material provided by the invention has the advantages of controllable drug release rate, good mechanical strength and biodegradability, is suitable for sustained-release delivery of Omega-3 fatty acid, vitamin D and other active components, and can improve the bioavailability and stability of drugs.

The present invention provides a solid dispersion of compound 1 or a pharmaceutical salt thereof, comprising the compound 1 or the pharmaceutical salt thereof as an active ingredient and a carrier material, wherein the carrier material is selected from one, two, or more of polyvinylpyrrolidone (PVP), copovidone, polyvinylpyrrolidone-vinyl acetate copolymer, hydroxypropyl methylcellulose acetate succinate, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, hydroxypropyl methylcellulose, polyethylene glycol, and ethyl cellulose, enabling the drug to have good stability, dissolution, and therapeutic effects. The formulation of the present invention provides rapid drug release and can reduce the oral burden of large-dose tablets on menopausal patients, thereby improving treatment compliance and treatment efficiency.

A rizatriptan microneedle patch, a preparation method therefor, and use thereof. The rizatriptan microneedle patch comprises a substrate and a needle body arranged on a surface of the substrate. The composition of the needle body comprises rizatriptan benzoate and a skeleton material. The skeleton material comprises a combination of dextran and trehalose, copovidone, a combination of polyvinyl alcohol and dextran, a combination of hypromellose and dextran, or a combination of sodium carboxymethyl cellulose and dextran. The rizatriptan microneedle patch has high mechanical strength and cumulative drug permeation.

The invention provides a sitagliptin and metformin sustained-release pharmaceutical composition as well as a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer, the sustained-release tablet core comprises an active ingredient metformin hydrochloride and a sustained-release framework material hydroxypropyl methylcellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises an active component sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methylcellulose in the sustained release tablet core is 50: (24-27). The composition utilizes a double-layer structure to realize double-phase release of the medicine; the microcrystalline cellulose is removed, and the specific ratio of the active component to the framework material is limited, so that the moldability and ideal dissolution behavior of the preparation are ensured while the tablet weight is remarkably reduced to improve the swallowing compliance, and the technical problem that the slow-release framework function is difficult to maintain under the condition that the weight of a high-drug-loading-capacity compound preparation is greatly reduced is successfully solved.

The invention belongs to the field of pharmaceutical preparations, and provides a medical composition for treating premature delivery and a preparation method thereof. The progesterone nanocrystal (D50 is 250-350 nm) and poloxamer 407 / 188 thermosensitive gel-forming system composite design is adopted, hydroxypropyl methylcellulose or carbomer 974P and a functional adhesion polymer (carbomer-cysteine or carbomer-catechol) are matched, the pH is adjusted to 4.0-4.5 through a lactic acid / sodium lactate buffer system, and the progesterone nanocrystal / poloxamer composite gel-forming agent is prepared. The excellent performance that the sol-gel transition temperature is 30-34 DEG C, the elastic modulus is not smaller than 150 Pa at 37 DEG C, the modulus retention rate is not smaller than 60% after the emulsion is diluted by 5-10 times, the adhesion work is not smaller than 0.60 N.s, and the anti-flushing retention rate is not smaller than 70% after the emulsion is diluted by 5-10 times is achieved. The invention solves the problem of synergy of high-modulus gel strength, rapid self-repairing ability and anti-dilution and anti-flushing stability, realizes unification of long-acting drug release and excellent biological adhesion performance in vagina physiological fluid dilution and mechanical flushing environments, and has wide clinical application value.

The application provides a sitagliptin and metformin hydrochloride sustained-release pharmaceutical composition and a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer; the sustained-release tablet core comprises active ingredients metformin hydrochloride and a sustained-release matrix material hydroxypropyl methyl cellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises active ingredients sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methyl cellulose in the sustained-release tablet core is 50:(24-27). The composition realizes double-phase release of drugs by using a double-layer structure; by removing the microcrystalline cellulose and limiting the specific ratio of active ingredients to the matrix material, the forming property of the preparation and the ideal dissolution behavior are ensured while the tablet weight is significantly reduced to improve the swallowing compliance, and the technical problem that a high drug loading compound preparation is difficult to maintain the function of the sustained-release matrix under a large amount of weight reduction is successfully solved.

The invention provides an effervescent tablet containing active probiotics and a preparation method thereof, and relates to the technical field of food and health care product processing. The preparation method of the effervescent tablet containing the active probiotics comprises the following steps: (1) acid granulation: coating an acid material with hydroxypropyl methylcellulose, and mixing with an adhesive and PEG 6000 for granulation; (2) alkali granulation: coating an alkali material with ethyl cellulose, mixing the coated alkali material with microcrystalline cellulose and an adhesive for granulation, and mixing with PEG (Polyethylene Glycol) 6000; (3) mixing the probiotic mixture by adopting an equivalent incremental method; (4) pre-pressing 30-40 kN of the acid particles to obtain an acid layer; and then sequentially filling a probiotic mixture and alkali particles, and finally pressing under the pressure of 50-60kN. According to the effervescent tablet containing the active probiotics, a double-layer tabletting technology is adopted, the survival rate of viable probiotics in the effervescent tablet is increased, and the disintegration time limit is shortened; and uniform bubbles and clear solution in the effervescing process are ensured.

The invention relates to the technical field of medicinal high polymer material synthesis, in particular to hydroxypropyl methylcellulose (HPMC) and a preparation method thereof, the method comprises the following steps: (1) pre-swelling treatment: mixing cotton powder with an isopropanol aqueous solution with the mass concentration of 10-20% according to the mass ratio of 1: (4-6), and pre-swelling at 20-25 DEG C for 30-60 minutes to obtain pre-swelled cotton powder; and (2) alkalization. (3) etherification: adding the etherification reagent into a reaction kettle, and enabling the etherification reagent to react with the alkalized refined cotton powder. (4) separating and drying; and (5) crushing: performing multi-stage gradient freeze-dried powder crushing on the dried material. And (6) obtaining a final product: mixing and packaging the crushed product. The HPMC product which is low in bulk density, fine in particle size and extremely small in batch-to-batch difference is prepared through the method, and it is ensured that the HPMC product has excellent and stable slow release performance when serving as a slow release framework material.

The present application relates to the technical field of pharmaceutical preparation, and provides a calcium carbonate tablet, which comprises the following raw materials in parts by weight: 700-800 parts of calcium carbonate, 80-100 parts of corn starch, 15-25 parts of low-substitution hydroxypropyl cellulose, 1.5-2.5 parts of polysorbate-80, 7-9 parts of protein sugar, 3-5 parts of hypromellose, 2.5-3.0 parts of magnesium stearate and 15-25 parts of sodium carboxymethyl starch; wherein the calcium carbonate is selected from calcium carbonate with a particle size of 40-80 μm; the low-substitution hydroxypropyl cellulose and the sodium carboxymethyl starch are disintegrants, and the ratio of the amount of the low-substitution hydroxypropyl cellulose to that of the sodium carboxymethyl starch is 1:1. The present application also provides a preparation method of the calcium carbonate tablet. The calcium carbonate tablet has the advantages of short disintegration time, high dissolution rate, good bioavailability and good stability.

The application discloses a white hypromellose hollow capsule, a preparation method and application thereof, and the composition of the hollow capsule comprises the following components in percentage by weight: 10-35 parts of hypromellose, 0.1-3 parts of a gelling agent, 0.2-3 parts of a complexing agent, 0.1-3 parts of a phosphate, 0.05-1 parts of an emulsifying agent, 0.05-1 parts of a coagulant, 0.01-1 parts of starch, 0-2 parts of a pigment, and the rest is water. The application discloses a white hypromellose hollow capsule with a whitening effect, which is obtained by adding the complexing agent and the phosphate and controlling the drying temperature and the drying time, and does not contain white pigment light-proof agents such as titanium dioxide, zinc oxide, calcium carbonate, barium sulfate and magnesium oxide. The hollow capsule has the advantages of uniform surface, good gloss, good uniformity, good light-proof property, small capsule weight difference, market demand satisfaction, and application in the fields of medicines and health products.

The invention discloses a coenzyme Q10 nanoparticle, which is prepared from the following raw materials in parts by weight: 0.16 to 0.2 part of coenzyme Q10, 8 to 10 parts of zein, 0.2 to 0.4 part of ethyl cellulose, 1 to 2 parts of sodium alginate and 0.2 to 0.4 part of hydroxypropyl methylcellulose. The invention also discloses a preparation method of the coenzyme Q10 nanoparticle. The preparation method comprises the following steps: dissolving coenzyme Q10, ethyl cellulose and zein in ethanol to obtain a solution A; dropwise adding the solution A into a mixed aqueous solution of sodium alginate and hydroxypropyl methylcellulose, stirring, and freeze-drying to obtain the coenzyme Q10 nanoparticles. The coenzyme Q10 nanoparticles disclosed by the invention have good encapsulation efficiency and hydrophobicity, and can keep water stable and improve the stability of the coenzyme Q10 nanoparticles; in addition, agglomeration of the nano-particles can be avoided, so that the nano-particles can be uniformly dispersed with other components and auxiliary materials to be matched for use.

A pharmaceutical composition comprising: an active pharmaceutical ingredient (API); 1-45 wt% non-gelatin matrix former comprising hydroxypropyl methylcellulose (hypromellose, HPMC), methyl cellulose,

This invention relates to a sustained-release eye drop and its preparation method, belonging to the field of ophthalmic drug technology. The invention provides a self-assembled microparticle comprising an elastin-like peptide and sodium hyaluronate; the molar ratio of the elastin-like peptide to sodium hyaluronate is 5-7:1-2; the amino acid sequence of the elastin-like peptide is shown in SEQ ID NO.1. The self-assembled microparticles of this invention have a sustained-release effect and exhibit synergistic properties with hydroxypropyl methylcellulose. The eye drops prepared by combining these two components possess excellent sustained-release performance, adhesion, and stability, allowing for prolonged application to the eye, effectively solving the problem of short duration of action in existing eye drops.

The invention relates to the technical field of traditional Chinese medicine preparations, and discloses a novel pill for treating diabetes mellitus and a preparation method, and the novel pill comprises the following raw materials in parts by mass: 30-40 parts of Chinese yam, 10-15 parts of poria cocos, 20-25 parts of radix polygonati officinalis, 25-35 parts of guava, 30-35 parts of radix rehmanniae recen, 28-32 parts of radix puerariae, 30-35 parts of corn stigma, 20-30 parts of radix trichosanthis, 25-30 parts of acanthopanax and 20-30 parts of rhizoma polygonati. The preparation method comprises the following steps: S1, screening, cleaning, crushing and homogenizing; s2, performing protein denaturation treatment, performing multi-stage enzymolysis, performing enzyme inactivation and filtration, and performing ultrafiltration membrane separation; s3, carrying out gene fusion to construct a fusion gene expression vector, transferring into pichia pastoris for expression, and purifying; s4, wrapping the target peptide fragment with the human albumin fusion protein; and S5, by taking the hydroxypropyl methylcellulose aqueous solution as an adhesive, molding in a pill pan, pelleting, shaping and drying.

This invention belongs to the field of biopharmaceutical technology and discloses a tranexamic acid sustained-release composition, its preparation process, and its application. By weight, the composition comprises 100-120 parts tranexamic acid, 14-18 parts sustained-release material, 5-8 parts magnesium stearate, 2-5 parts colloidal silica, and 3-5 parts polyvinyl alcohol. The sustained-release material is selected from a combination of hydroxypropyl cellulose and ethyl cellulose, or a combination of hydroxypropyl methyl cellulose and microcrystalline cellulose, or a combination of sodium carboxymethyl cellulose and hydrogenated vegetable oil. This invention utilizes the synergistic effect of the sustained-release material and the synergistic effect between the sustained-release material and polyvinyl alcohol to maintain zero-order or first-order release of the drug, achieving a steady-state blood drug concentration and prolonging the duration of action, thereby achieving a good sustained-release effect.

The invention provides a composition containing picocetinib hydrobromide and a preparation method thereof, the composition is a tablet, the active component picocetinib hydrobromide and a hydrophilic gel framework material (e.g., hydroxypropyl methylcellulose, polyoxyethylene resin or hydroxypropyl methyl cellulose acetate succinate) form a solid dispersion, and the solid dispersion is prepared into the composition containing the picocetinib hydrobromide and the hydrophilic gel framework material (e.g., hydroxypropyl methylcellulose, polyoxyethylene resin or hydroxypropyl methyl cellulose acetate succinate). The solubility of the medicine is improved, and stable release in vivo is realized; according to the present invention, with the addition of the pH value adjusting agent, the solubility of the picetinib hydrobromide can be maintained without limitation in the neutral pH region, the stability is good, and the stable release in the body is achieved so as to achieve the rheumatic arthritis treatment effect, improve the patient comfort and the treatment compliance, reduce the administration frequency and the medical cost, reduce the side effect, and provide the clinical application prospect. The whole preparation method is simple and suitable for industrial production.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a minocycline hydrochloride-melatonin compound colon targeting capsule and a preparation method thereof. The capsule comprises a pellet and a capsule shell, wherein the pellet comprises a medicine core and a colon-targeted sustained-release layer wrapping the medicine core. The medicine core comprises active ingredients of minocycline hydrochloride and melatonin; the colon-targeted sustained-release layer comprises a special pH-enzyme colon-targeted response agent and a self-made plasticizer. The pH-enzyme responsive agent is based on a hydroxypropyl methylcellulose grafted vanillin derivative, and can be degraded in response to pH change and azo reductase at the colon part; the plasticizer has good compatibility with a coating material, and can effectively reduce leakage of drugs at the front ends of the stomach and intestines. The capsule prepared by the invention can obviously improve gastrointestinal stimulation of minocycline hydrochloride, realizes targeted release of the medicine at the colon part, and shows an excellent treatment effect on ulcerative colitis while reducing the dosage of antibiotics by utilizing the synergistic effect of melatonin.

The invention belongs to the field of pharmaceutical preparations, and provides a postpartum hemorrhage treatment composition and a preparation method thereof, the preparation adopts a double-layer microstructure design: a surface layer is a microporous quick release layer of 0.5-5 [mu] m, a substrate layer is a compact bearing layer, and the total film thickness is 20-60 [mu] m. According to the preparation method, hydroxypropyl methylcellulose and 2-hydroxypropyl-beta-cyclodextrin are taken as matrixes, the mass ratio of hydroxypropyl methylcellulose to 2-hydroxypropyl-beta-cyclodextrin is (80-150): 1 and (10-40): 1 (relative to misoprostol), free water is controlled to be less than or equal to 2.0 wt% through two sections of drying curves in a low-dew-point environment, a cyclodextrin nano-domain with the median diameter of 80-200 nm is formed through induction, the disintegration time is less than or equal to 45 seconds, the onset time is less than or equal to 10 minutes, and the sustained release tablet is prepared. Meanwhile, the film preparation has excellent mechanical strength and chemical stability, solves the contradiction between quick release and structural integrity, between low water content stability and quick dissolution, and between thickness uniformity and nano domain formation in the existing film preparation, and has important clinical application value.

The invention discloses a tartaric acid pellet and a preparation method thereof, the tartaric acid pellet is prepared from tartaric acid, an auxiliary material and an adhesive by adopting a centrifugal granulation process, the auxiliary material is one of low-substituted hydroxypropyl methylcellulose, microcrystalline cellulose and citric acid, the adhesive is purified water, and when the auxiliary material is the low-substituted hydroxypropyl methylcellulose, 90% < / = 1t tartaric acid, 0% < / = 1t tartaric acid, 0% < / = 1t tartaric acid, 0% < / = 1t tartaric acid, and 0% < / = 1t tartaric acid. 100%, 0 lt; less than or equal to 10% of low-substituted hydroxypropyl methylcellulose; when the auxiliary material is microcrystalline cellulose, 70% is less than or equal to 1t of tartaric acid; 100%, 0 lt; microcrystalline cellulose < = 30%; when the auxiliary material is citric acid, 90% is not more than 1t of tartaric acid; 100%, 0 lt; citric acid < = 10%; when no auxiliary material exists, the content of tartaric acid is 100%. Tartaric acid is used as a basic raw material, low-substituted hydroxypropyl methylcellulose or microcrystalline cellulose or citric acid is used as an auxiliary material, or no auxiliary material is used, purified water is used as an adhesive to prepare the tartaric acid pellet, the varieties of the auxiliary materials are few, the generation interference of impurities can be reduced for the tartaric acid pellet, the medicine quality is improved, and the quality risk is reduced.

The invention relates to a pH responsive hydrogel drug delivery system for corneal neovascularization treatment, which is a composite hydrogel LEV-DG-HPMC formed by forming LEV-DG nano-micelles from drugs levofloxacin and dipotassium glycyrrhizinate by a film dispersion method, then heating and self-assembling to form LEV-DG hydrogel, and introducing hydroxypropyl methylcellulose as a tackifier. The drug delivery system disclosed by the invention has unique pH response characteristics, can accurately identify the alkali burn microenvironment and control the release of drugs, and obviously prolongs the cornea residence time. Through the synergistic effect of DG and LEV, the vicious circle of infection-inflammation-neovascularization is effectively blocked. Experiments show that the system can significantly reduce the corneal neovascularization area and accelerate epithelium repair, has good biocompatibility and treatment effect, and provides a new solution for treatment of corneal alkali burn.

The invention relates to the technical field of detergents, in particular to a tea saponin-containing antibacterial detergent and a preparation method thereof. The preparation method comprises the following steps: mixing deionized water, tea saponin, dodecylbenzene sulfonic acid, vanillin, guar gum, glycerol, aromatherapy essential oil, a zeolite silver-loaded antibacterial agent and sodium hydroxide, and granulating to obtain tea saponin-containing antibacterial detergent powder; taking an oxidized starch-gelatin composite gel solution as a capsule inner shell wall material, reacting ethylenediamine tetraacetic acid with chitosan to obtain a chelating agent, mixing the chelating agent with a hydroxypropyl methylcellulose solution to obtain an outer shell wall material, and spraying the outer shell wall material to the surface of the capsule inner shell wall material to obtain a composite capsule shell; and packaging the tea saponin-containing antibacterial detergent powder by using the composite capsule shell to obtain the tea saponin-containing antibacterial detergent. The detergent prepared by the invention is good in foaming ability and strong in decontamination effect, and also has excellent antibacterial performance.

The invention provides a budesonide temperature-sensitive gel preparation as well as a preparation method and application thereof, and the budesonide temperature-sensitive gel preparation is mainly prepared from the following components: budesonide, poloxamer 407, poloxamer 188, propylene glycol, hydroxypropyl methyl cellulose, sodium benzoate and pure water. After the budesonide temperature-sensitive gel drug delivery system based on poloxamer 407, poloxamer 188 and hydroxypropyl methylcellulose is applied to a cavity, semi-solid gel can be quickly formed, and strong retention and slow release effects are shown, so that the bioavailability is increased, the formed semi-solid gel can be retained at a drug delivery part and cannot be lost, and the budesonide temperature-sensitive gel drug delivery system is suitable for clinical application. In addition, budesonide can be gradually released, and a remarkable curative effect is shown in short-term clinical application of recurrent chronic sinusitis with nasal polyp.

The present application relates to the technical field of hydrogen absorption, in particular to a three-layer coated hydrogen absorption oxygen and water blocking microcapsule, a preparation method and application thereof, wherein hydrogen absorption powder is pressed into tablets and then coated with three layers, and the coating solution used in the coating contains hydroxypropyl methyl cellulose, polystyrene and / or reduced graphene oxide. By adding PS and rGO as coating materials and selecting a suitable thickness for coating, the hydrogen absorption microcapsule has the characteristics of hydrogen absorption, oxygen blocking and water blocking.

The invention relates to a brexpiprazole oral soluble film and a preparation method thereof, the film agent does not use a thickening agent, and comprises 2%-10% of brexpiprazole, 60%-90% of a polymer film-forming material and 5%-30% of a plasticizer; the polymer film-forming material is a composition of hydroxypropyl methylcellulose and hydroxy propyl cellulose. The prepared brexpiprazole oral soluble film is flat in appearance, free of curl, uniform and smooth, free of visible particles, capable of being disintegrated rapidly and good in tensile strength and stability.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a roxithromycin preparation and a preparation method thereof. The roxithromycin preparation is prepared from the following raw materials: roxithromycin, a stabilizer, a glidant, a filler, a binder and a lubricant. The stabilizer is a mixture of hydroxypropyl methyl cellulose and povidone. The glidant is talc. The stabilizer system used in the traditional high-pressure homogenization technology (HPH) is optimized according to the particularity of the roxithromycin raw material. The hydroxypropyl methyl cellulose and the povidone are used together, and the talc is introduced to improve the powder properties of the prepared nanocrystals, so that the subsequent production and manufacturing are facilitated. The preparation prepared according to the method has stable drug quality and accurate dosage.

The invention discloses a preparation method of roselle hangover-alleviating buccal tablets, and particularly relates to the field of preparation methods. The lozenge is prepared from the following raw materials in parts by weight: 5-15 parts of a roselle extract, 5-15 parts of a radix puerariae powder extract, 1-5 parts of hydroxypropyl methylcellulose, 5-10 parts of xylitol, 0.5-1.5 parts of magnesium stearate and 1000ml of water. The preparation method of the lozenge comprises the following steps: S1, weighing the raw materials in parts by weight; s2, uniformly mixing the roselle extract, the radix puerariae powder extract, xylitol and hydroxypropyl methylcellulose to obtain a mixed material; and S3, adding magnesium stearate into the mixed material, uniformly mixing, and tabletting to obtain the roselle alcohol effect dispelling lozenge. The problem that an existing anti-alcoholism product cannot give consideration to both high efficiency and safety is solved, and the economic added value of the roselle is improved.

The invention discloses fluconazole ear drops and a preparation method of the fluconazole ear drops, and belongs to the technical field of ear drop preparations. The composition comprises the following components in percentage by mass: 0.6%-2.0% of fluconazole, 8%-20% of propylene glycol and / or diethylene glycol monoethyl ether, 20%-32% of glycerol or caprylic / capric polyethylene glycol glyceride, 0.1%-1% of hydroxypropyl methylcellulose, 0.05%-0.2% of anhydrous disodium hydrogen phosphate and the balance of anhydrous citric acid and water. By improving the prescription of the fluconazole ear drops, the solubility of the fluconazole is increased, the content of the fluconazole in the prepared fluconazole ear drops reaches 2%, the fluconazole ear drops are good in stability, and compared with the prior art, the fluconazole ear drops have a better treatment effect on ear fungal infection.

The application discloses a duloxetine hydrochloride enteric-soluble capsule, which is composed of a capsule shell and content, wherein the content is a micro-pellet containing duloxetine hydrochloride, and the micro-pellet is composed of a blank pellet core, a drug-loading layer, an isolation layer, an enteric-soluble layer and a protective layer. The binder of the isolation layer of the enteric-soluble capsule micro-pellet contains both high-viscosity hypromellose and low-viscosity hypromellose. Through improvement of the composition of the isolation layer, the dissolution curve of the duloxetine hydrochloride enteric-soluble capsule meets the standard requirements, the 90-minute dissolution degree is obviously improved, and the stability is superior to that of a reference preparation.

This invention discloses an amoxicillin capsule and its preparation method, relating to the field of pharmaceutical technology. The preparation method includes the following steps: S1: Wet ball milling of amoxicillin trihydrate and hydroxypropyl methylcellulose E5, followed by spray drying to obtain surface-modified amoxicillin trihydrate micropowder; S2: Mixing the surface-modified amoxicillin trihydrate with a filler; S3: Fluidized bed granulation, including spray granulation using aqueous ethanol as a wetting agent followed by drying; S4: Granulation and mixing, including granulating the dried particles and then adding a disintegrant, a flow aid, and a lubricant; S5: Capsule filling, including capsule filling with controlled ambient humidity. This invention achieves the goals of maintaining the crystal stability of amoxicillin trihydrate, inhibiting hydrothermal degradation, and ensuring dissolution behavior consistent with the original drug by combining wet ball milling of hydroxypropyl methylcellulose E5 with spray drying for surface modification, fluidized bed granulation with aqueous ethanol, and controlling the humidity of the filling environment.

The present application provides a traditional Chinese medicine composition for preventing and treating metabolic-associated fatty liver disease, a capsule, and use. The traditional Chinese medicine composition is prepared from the following starting materials in parts by weight: 1-5 parts of Curcumae Longae Rhizoma extract, 10-20 parts of Puerariae Lobatae Radix extract, 15-30 parts of Salviae Miltiorrhizae Radix et Rhizoma extract, 1-10 parts of Schisandrae Chinensis Fructus extract, and 2-15 parts of Ganoderma extract. The preparation method for the capsule comprises the following steps: mixing the Curcumae Longae Rhizoma extract, the Puerariae Lobatae Radix extract, the Salviae Miltiorrhizae Radix et Rhizoma extract, the Schisandrae Chinensis Fructus extract, the Ganoderma extract, and maltodextrin uniformly, and filling the mixture into a hydroxypropyl methylcellulose hollow capsule to give the capsule. Salviae Miltiorrhizae Radix serves as the sovereign medicinal, Curcumae Longae Rhizoma and Puerariae Lobatae Radix serve as ministerial medicinals, and Schisandrae Chinensis Fructus and Ganoderma serve as adjuvant medicinals, such that the combination of such medicinals achieves the effects of protecting the liver, promoting blood circulation and regulating the flow of qi, promoting the production of body fluids and quenching thirst, tonifying qi for tranquillization, and the like. The present application can effectively prevent and treat metabolic-associated fatty liver disease and can treat non-alcoholic fatty liver disease, especially achieving a significant therapeutic effect on the non-alcoholic simple fatty liver and non-alcoholic steatohepatitis.